Novocure Ltd (NASDAQ:NVCR) CFO Wilhelmus Cm Groenhuysen sold 25,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $79.57, for a total transaction of $1,989,250.00. Following the completion of the transaction, the chief financial officer now owns 112,179 shares in the company, valued at approximately $8,926,083.03. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Wilhelmus Cm Groenhuysen also recently made the following trade(s):

  • On Monday, September 9th, Wilhelmus Cm Groenhuysen sold 25,000 shares of Novocure stock. The shares were sold at an average price of $80.83, for a total transaction of $2,020,750.00.

NVCR traded down $0.96 on Friday, reaching $79.29. The company had a trading volume of 416,807 shares, compared to its average volume of 741,332. The company’s fifty day moving average is $86.81 and its 200 day moving average is $61.61. Novocure Ltd has a fifty-two week low of $26.02 and a fifty-two week high of $98.70. The stock has a market cap of $7.88 billion, a P/E ratio of -114.91 and a beta of 2.41. The company has a debt-to-equity ratio of 1.01, a quick ratio of 4.68 and a current ratio of 5.03.

Novocure (NASDAQ:NVCR) last announced its earnings results on Thursday, July 25th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.06. Novocure had a negative net margin of 13.84% and a negative return on equity of 31.80%. The firm had revenue of $86.70 million for the quarter, compared to analyst estimates of $78.98 million. During the same quarter in the prior year, the business posted ($0.17) EPS. The business’s revenue was up 41.0% compared to the same quarter last year. On average, sell-side analysts expect that Novocure Ltd will post -0.22 EPS for the current year.

Large investors have recently made changes to their positions in the business. Chicago Equity Partners LLC grew its position in shares of Novocure by 14.5% during the 2nd quarter. Chicago Equity Partners LLC now owns 50,925 shares of the medical equipment provider’s stock worth $3,220,000 after purchasing an additional 6,435 shares in the last quarter. Wedbush Securities Inc. acquired a new position in shares of Novocure during the 2nd quarter worth approximately $241,000. Baillie Gifford & Co. grew its position in shares of Novocure by 9.8% during the 2nd quarter. Baillie Gifford & Co. now owns 8,829,449 shares of the medical equipment provider’s stock worth $558,287,000 after purchasing an additional 789,924 shares in the last quarter. Jennison Associates LLC grew its position in shares of Novocure by 13.8% during the 2nd quarter. Jennison Associates LLC now owns 16,032 shares of the medical equipment provider’s stock worth $1,014,000 after purchasing an additional 1,940 shares in the last quarter. Finally, C WorldWide Group Holding A S grew its position in shares of Novocure by 92.5% during the 2nd quarter. C WorldWide Group Holding A S now owns 208,059 shares of the medical equipment provider’s stock worth $13,156,000 after purchasing an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 66.50% of the company’s stock.

A number of brokerages recently commented on NVCR. SunTrust Banks upgraded shares of Novocure from a “hold” rating to a “buy” rating in a research note on Monday, July 29th. BidaskClub lowered shares of Novocure from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 5th. ValuEngine upgraded shares of Novocure from a “buy” rating to a “strong-buy” rating in a research note on Friday, July 26th. Mizuho upped their price target on shares of Novocure from $63.00 to $91.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, TheStreet upgraded shares of Novocure from a “d” rating to a “c-” rating in a research note on Friday, July 26th. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $68.00.

About Novocure

Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline.

Further Reading: Purposes and Functions of the Federal Reserve

Insider Buying and Selling by Quarter for Novocure (NASDAQ:NVCR)

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.